FDA rejects oral treprostinil diolamine for pulmonary arterial hypertension

Source: Reuters Health News Area: News Reuters Health News has reported that the US Food and Drug Administration (FDA) has denied approval of oral treprostinil diolamine for the treatment of pulmonary arterial hypertension. The drug was first rejected by the FDA in October 2012 after it had failed to show statistically significant results in patients taking the six-minute walk test during clinical studies.   The report does not provide information on the reasons for the rejection.   [Editor's note: Treprostinil is not licensed in the UK.]
Source: NeLM - Cardiovascular Medicine - Category: Cardiology Source Type: news